Cytomegalovirus (CMV) is a globally ubiquitous herpesvirus that establishes a lifelong latent reservoir after infection \[[@CIT0001]\]. Congenital CMV infection causes permanent disability and birth defects \[[@CIT0001]\]. In individuals with weakened immune systems, such as transplant patients or persons living with human immunodeficiency virus, CMV infection can cause severe disease \[[@CIT0001], [@CIT0004], [@CIT0005]\]. Although CMV infection is typically asymptomatic in healthy individuals, it has been associated with inflammation and immunosenescence as well as cognitive decline, cancer, and all-cause mortality \[[@CIT0001], [@CIT0006]\].

The presence of CMV immunoglobulin (Ig)G antibodies indicates prior exposure to CMV \[[@CIT0001]\]. Cytomegalovirus transmission typically occurs by direct or indirect contact with the bodily fluids of a person who is actively shedding the virus. Cytomegalovirus infects many tissue types; consequently, CMV shedding occurs via multiple fluids, such as saliva, urine, and genital secretions \[[@CIT0001], [@CIT0007]\]. Cytomegalovirus shedding is common after initial infection, reinfection with a new strain, or reactivation of latent virus \[[@CIT0001]\]. Different CMV strains are identified by gene variants such as those found in viral envelope glycoprotein B (gB) and glycoprotein H (gH) \[[@CIT0010]\]. The genotypic distribution of CMV is largely unknown in general populations.

The National Health and Nutrition Examination Survey (NHANES) is the largest population-based study to monitor the epidemiology of CMV infection in the United States. In the 1999--2004 NHANES, CMV seroprevalence was estimated to be 50.4% among persons aged 6--49 years \[[@CIT0011]\]. Using the same data source, Amin et al \[[@CIT0012]\] showed that the prevalence of urinary CMV shedding was 9.7% among CMV-seropositive persons aged 6--49 years. Although CMV IgG seroprevalence increased with age into adulthood \[[@CIT0011]\], prevalence of urinary CMV shedding decreased with age among CMV-seropositive individuals \[[@CIT0012]\]. In age-adjusted analyses of CMV-seropositive 6- to 49-year-olds, Amin et al \[[@CIT0012]\] showed that the detection of urinary CMV shedding was associated with female sex and household income level. However, the cited study did not examine the correlates of urinary CMV shedding among CMV-seropositive children and adolescents---the population that has the highest probability of urinary CMV shedding. The increased prevalence of urinary CMV shedding in pediatric populations is likely reflective of recent primary infection \[[@CIT0002], [@CIT0012]\]. Thus, we hypothesized that the determinants of urinary CMV shedding are likely different in pediatric and adult populations. In this study, data from the 1999--2004 NHANES were used to examine the prevalence, magnitude, genotype distribution, and correlates of urinary CMV shedding among CMV-seropositive children and adolescents aged 6--19 years.

METHODS {#s1}
=======

Study Design and Population {#s2}
---------------------------

A cross-sectional analysis was performed on data from the 1999--2004 NHANES, which was conducted by the National Center for Health Statistics (NCHS) of the Center for Disease Control and Prevention. The NHANES uses a stratified, multistage probability sampling design to select study participants that are representative of the US noninstitutionalized civilian population. Respondents participated in a household interview and a follow-up physical examination at a local mobile examination center (MEC) \[[@CIT0013]\]. At the MEC, participants had venous blood samples drawn and provided self-administered urine samples. Individuals aged 6--49 years with available stored serum were eligible to have their serum tested for CMV IgG antibody. Individuals who were seropositive for CMV IgG, had available stored urine samples, and identified as non-Hispanic white, non-Hispanic black, or Mexican American were eligible to be tested for urinary viral shedding.

Of the 12 072 6- to 19-year-olds that were screened to enroll in NHANES between 1999 and 2004, 10 235 (84.8%) participated in the medical examination component of NHANES ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). The analytic sample for the present study consisted of 9546 examinees aged 6--19 years who identified as non-Hispanic white, non-Hispanic black, or Mexican American.

Ethics Statement {#s3}
----------------

Data collection and study procedures were approved by the NCHS Research Ethics Board. This analysis of deidentified and publicly available data was deemed exempt from review by the Johns Hopkins University School of Medicine Institutional Review Board.

Laboratory Testing {#s4}
------------------

Measures of CMV IgG antibody status and urinary CMV shedding were conducted on surplus serum and urine samples. These samples were stored at the NHANES surplus biorepository at −80°C \[[@CIT0014]\]. Cytomegalovirus IgG status was measured on serum samples by enzyme-linked immunosorbent assay (ELISA) (Quest International, Inc., Miami, FL) and confirmed with a second ELISA (bioMerieux, Inc., Durham, NC) and/or immunofluorescence assay (Bion International, Inc., Woodburn, MA) \[[@CIT0011]\]. Deoxyribonucleic acid (DNA) was extracted from urine samples of CMV IgG-seropositive persons (QIAGEN, Valencia, CA) \[[@CIT0012], [@CIT0015]\]. Urinary CMV DNA was detected by real-time polymerase chain reaction (PCR) of the immediate early-2 region of the viral genome \[[@CIT0015], [@CIT0016]\]. Viral loads were quantified using commercially standardized CMV DNA from Advanced Biotechnologies, Inc. (Eldersburg, MD) \[[@CIT0012]\]. All CMV PCR testing was performed in duplicate, and both tests were required to be positive for an individual to be categorized as shedding the virus \[[@CIT0012]\]. Urine samples that had sufficient CMV DNA were genotyped for 4 gB and 2 gH variants \[[@CIT0017], [@CIT0018]\].

Blood hemoglobin was measured using a single-beam photometer, and lymphocyte count was derived using the Beckman-Coulter method on the Beckman Coulter MAXM Hematology Analyzer. C-reactive protein levels were estimated in sera by latex-enhanced nephelometry using the Dade Behring Nephelometer II Analyzer System. Urinary albumin was measured using solid-phase fluorescent immunoassay on a Sequoia-Turner Fluorometer, model 450. Urinary creatinine was estimated by the colorimetric Jaffe method on the Beckman Synchron CX3 Clinical Analyzer.

Statistical Analysis {#s5}
--------------------

The analysis was weighted to account for the complex survey design, unless specified otherwise. The medical examination weights provided by NCHS were pooled across the 3 cycles and used to adjust for differential probabilities of selection, unit nonresponse to the medical exam component, and noncoverage of the noninstitutionalized US civilian population. Taylor series linearization was used to estimate design-corrected (robust) standard errors.

Cytomegalovirus IgG antibody prevalence was estimated among all eligible participants who attended the medical examination component. Urinary CMV shedding prevalence was estimated among CMV IgG antibody-positive individuals. Geometric mean urinary CMV viral loads were estimated among those with detectable urinary CMV shedding. Poisson regression was used to examine associations of sociodemographic, behavioral, and clinical variables with prevalence of urinary CMV shedding among CMV IgG antibody-positive individuals. Variables associated with prevalent CMV shedding using a design-adjusted Wald *F*-test (*P* \< .15) and/or deemed to be important a priori (eg, age, sex, and race/ethnicity) were included in multivariable analysis.

There were missing data on key variables ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). For instance, in the analytic sample (n = 9546), 17.2% of participants were missing data on CMV IgG antibody status. Urinary CMV shedding data was missing for 17.1% of the 4032 participants who were identified to be CMV IgG-antibody positive. Variables outside of age, race/ethnicity, and sex were associated with missing data on CMV IgG antibody and urinary CMV shedding, such as household crowding ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Multiple imputation with chained equations was performed to handle missing data, assuming data were missing at random (ie, missing data could be explained by observed characteristics). The imputation model included variables related to the complex survey design (eg, survey weights), all variables in the analysis, and auxiliary variables associated with missing data. The imputation process was conducted in a stepwise manner for CMV outcomes; for example, CMV shedding status was only imputed if the participant was identified as CMV IgG seropositive in a given imputed data set. Forty complete data sets were generated and results were combined using Rubin's rules \[[@CIT0019]\]. All weighted analyses were conducted using -mi est- and -svy- commands in Stata/MP, version 15.2 (StataCorp LP, College Station, TX).

In a separate analysis, the genotype distribution of urinary CMV shedders was examined in the unweighted observed data set (ie, those who had sufficient DNA for genotyping). We used an available-case analytic approach when examining genotype data, because there was poor information in the dataset to inform an imputation.

RESULTS {#s6}
=======

Prevalence and Magnitude of Urinary Cytomegalovirus Shedding {#s7}
------------------------------------------------------------

In the study population, the prevalence of CMV IgG antibody was 39.6% (95% confidence interval \[CI\], 36.9%--42.3%). Among CMV IgG-seropositive individuals, the prevalence of urinary shedding was 15.5% (95% CI, 13.1%--17.9%). The prevalence of CMV IgG antibody increased overall with older age ([Figure 1A](#F1){ref-type="fig"}). In contrast, the prevalence of urinary CMV shedding among CMV IgG-seropositive individuals decreased overall with older age ([Figure 1B](#F1){ref-type="fig"}). Children aged 6--8 years had a higher prevalence of urinary CMV shedding (34.4%) compared to 9- to 11-year-olds (20.6%, *P* = .003), 12- to 14-year-olds (7.8%, *P* \< .001), 15- to 17-year-olds (6.9%, *P* \< .001), and 18- to 19-year-olds (5.8%, *P* \< .001). There was a nonlinear relationship between age and urinary CMV viral loads among urinary CMV shedders ([Figure 1C](#F1){ref-type="fig"}).

![Weighted age-specific prevalence of cytomegalovirus (CMV) outcomes in the pediatric population aged 6--19 years, National Health and Nutrition Examination Survey, 1999--2004 (n = 9564). (A) Prevalence of CMV immunoglobulin (Ig)G antibody, (B) prevalence of urinary CMV shedding among the IgG-seropositive individuals, and (C) geometric mean urinary CMV viral loads among urinary CMV shedders were estimated accounting for the complex weighted survey design. Error bars reflect 95% confidence intervals estimated using Taylor series linearization and Rubin's rules. Asterisks represent a *P* value less than .05, indicating a statistically significant difference compared with 6- to 8-year-olds. *P* values were calculated from a *t* test.](ofz272f0001){#F1}

Correlates of Urinary Cytomegalovirus Shedding {#s8}
----------------------------------------------

Factors associated with the prevalence of urinary CMV shedding in the CMV IgG-seropositive population are shown in [Table 1](#T1){ref-type="table"}. Multivariable analysis included age, race/ethnicity, sex, annual family income, body mass index (BMI), lymphocyte count, and anemia. Older age and higher BMIs were independent factors negatively associated with the prevalence of urinary CMV shedding (*P* \< .05). For instance, the prevalence of urinary CMV shedding was significantly lower in obese individuals compared with persons who were of lean weight (adjusted prevalence ratio = 0.68; 95% CI, 0.47--0.99). No other variables were independently associated with urinary CMV shedding in the CMV IgG-seropositive population.

###### 

Factors Associated With Urinary CMV Shedding Among CMV IgG-Seropositive 6- to 19-Year-Olds, National Health and Nutrition Examination Survey, 1999--2004 (n = 9546)

  Characteristic                         CMV Shedding Prevalence (95% CI)   Univariable PR (95% CI)   *P* Value    Multivariable PR (95% CI)   *P* Value
  -------------------------------------- ---------------------------------- ------------------------- ------------ --------------------------- ------------
  Age, Years                                                                                                                                   
   6--8                                  34.4 (26.2--42.6)                  Ref.                                   Ref.                        
   9--11                                 20.6 (15.6--25.5)                  **0.60 (0.43--0.83)**     **.003**     **0.61 (0.44--0.83)**       **.003**
   12--19                                7.0 (5.4--8.6)                     **0.20 (0.14--0.29)**     **\<.001**   **0.21 (0.14--0.30)**       **\<.001**
  Sex                                                                                                                                          
   Male                                  15.1 (11.7--18.6)                  Ref.                                   Ref.                        
   Female                                15.8 (12.9--18.8)                  1.04 (0.79--1.38)         .745         1.07 (0.82--1.40)           .586
  Race/Ethnicity                                                                                                                               
   Non-Hispanic White                    14.9 (10.8--19.0)                  Ref.                                   Ref.                        
   Non-Hispanic Black                    18.1 (15.4--20.7)                  1.22 (0.89--1.66)         .210         1.22 (0.89--1.67)           .204
   Mexican American                      14.3 (11.7--16.9)                  0.96 (0.68--1.37)         .816         0.96 (0.68--1.34)           .784
  Annual Family Income                                                                                                                         
   \<\$35 000                            17.1 (14.0--20.1)                  Ref.                                   Ref.                        
   ≥\$35 000                             13.5 (10.2--16.9)                  0.79 (0.59--1.06)         .108         0.85 (0.64--1.12)           .226
  Household Crowding^a^                                                                                                                        
   \<0.75 people per room                14.7 (10.8--18.6)                  Ref.                                                               
   0.75--0.9 people per room             13.9 (9.0--18.8)                   0.94 (0.59--1.50)         .785                                     
   ≥1 person per room                    17.8 (14.3--21.3)                  1.21 (0.87--1.68)         .240                                     
  Recent Health in Past 30 Days^b^                                                                                                             
   Not sick                              15.2 (12.4--18.0)                  Ref.                                                               
   Sick                                  16.2 (12.3--20.0)                  1.06 (0.80--1.42)         .672                                     
  Maximum Household Education^c^                                                                                                               
   Less than high school                 16.6 (12.9--20.3)                  Ref.                                                               
   High school or GED                    17.4 (12.3--22.5)                  1.05 (0.73--1.50)         .799                                     
   Some college or more                  13.9 (10.8--17.0)                  0.84 (0.61--1.15)         .256                                     
  Body Mass Index^d^                                                                                                                           
   Lean                                  17.0 (13.9--20.2)                  Ref.                                   Ref.                        
   Overweight                            13.5 (9.2--17.7)                   0.79 (0.55--1.14)         .196         0.82 (0.58--1.14)           .227
   Obese                                 11.3 (7.3--15.3)                   **0.66 (0.45--0.98)**     **.038**     **0.68 (0.47--0.99)**       **.043**
  Log-lymphocyte count (1000 cells/μL)                                      **1.93 (1.23--3.03)**     **.006**     1.03 (0.66--1.62)           .889
  Albuminuria (Albumin/Creatinine)                                                                                                             
   Normal (\<30 mg/g)                    15.2 (12.9--17.5)                  Ref.                                                               
   Albuminuria (≥30 mg/g)                18.1 (9.9--26.3)                   1.19 (0.76--1.86)         .430                                     
  C-Reactive Protein Quartiles (mg/dL)                                                                                                         
   1 (≤0.02)                             17.5 (12.7--22.2)                  Ref.                                                               
   2 (0.03--0.05)                        15.7 (11.2--20.1)                  0.90 (0.63--1.29)         .543                                     
   3 (0.06--0.16)                        13.8 (9.8--17.8)                   0.79 (0.53--1.17)         .225                                     
   4 (\>0.16)                            13.6 (9.5--17.7)                   0.78 (0.51--1.19)         .236                                     
  Anemia^e^                                                                                                                                    
   Normal                                14.1 (11.6--16.7)                  Ref.                                   Ref.                        
   Anemic                                21.5 (16.1--27.0)                  **1.52 (1.13--2.06)**     **.009**     1.01 (0.74--1.39)           .946

Abbreviations: CDC, Centers for Disease Control and Prevention; CI, confidence interval; CMV, cytomegalovirus; GED, General Education Diploma; IgG, immunoglobulin G; MEC, mobile examination center; PR, prevalence ratio; Ref., reference group.

NOTE: Data are weighted prevalence estimates and PRs calculated by Poisson regression. Taylor series linearization was used to estimate standard errors. Estimates were also calculated using Rubin's rules. Bolded numbers indicate statistically significant estimates (*P* \< .05).

^a^Household crowding was calculated by dividing the number of persons living in the home by the number of rooms in the home, excluding the kitchen.

^b^Recent health in the past 30 days was defined as a response of "yes" to having a head cold, chest cold, stomach or intestinal illness with vomiting or diarrhea, the flu, pneumonia, or an ear infection in the 30 days before the MEC examination.

^c^Maximum household education is the highest level of education achieved by either the head of household or their spouse.

^d^Body mass index (BMI) categories were defined by the CDC pediatric BMI-for-age weight status categories, where individuals were considered lean at \<85th percentile, overweight at ≥85th to \<95th percentile, and obese at ≥95th percentile.

^e^Anemia was defined as hemoglobin levels ≤12g/dL for females and ≤13.5g/dL for males.

Genotype Distribution of Urinary Cytomegalovirus Shedding {#s9}
---------------------------------------------------------

[Figure 2](#F2){ref-type="fig"} shows the unweighted prevalence of 4 gB and 2 gH variants among urinary CMV shedders with sufficient CMV DNA for genotyping in the observed data set. A gB variant was detected among 71.6% (174 of 243) of urinary CMV shedders who had sufficient CMV DNA for gB genotyping. Among those with a detectable gB variant (n = 174), 150 (86.2%) had a single gB variant detected, whereas 24 (13.8%) had multiple (≥2) gB variants detected; the most commonly detected gB variant was gB1 (n = 89; 51.1%) followed by gB2 (n = 51; 29.3%), gB3 (n = 37; 21.3%), and gB4 (n = 22; 12.6%). A gH variant was detected among 88.1% (214 of 243) of urinary CMV shedders who had sufficient CMV DNA for gH genotyping. Among those with a detectable gH variant (n = 214), 198 (92.5%) had a single gH variant detected, whereas 16 (7.5%) had both gH1 and gH2 variants detected. Detection of gH2 (n = 128; 59.8%) was more common than gH1 (n = 102; 47.7%).

![Unweighted prevalence of cytomegalovirus (CMV) genotype-specific variants among urinary CMV shedders in the pediatric sample aged 6--19 years, National Health and Nutrition Examination Survey, 1999--2004. (A) Prevalence of each glycoprotein B (gB) variant was estimated among 174 participants with data on gB. (B) Prevalence of each glycoprotein H (gH) variant was estimated among 214 participants with data on gH.](ofz272f0002){#F2}

DISCUSSION {#s10}
==========

To the best of our knowledge, this is the largest population-based study to characterize urinary CMV shedding and the genotype distribution of CMV infections among 6- to 19-year-olds in the United States. In this population, the prevalence and magnitude of urinary CMV shedding among CMV IgG-seropositive individuals was significantly associated with age. Younger children had a higher prevalence of urinary CMV shedding and higher viral loads compared with adolescents. Although Amin et al \[[@CIT0012]\] assumed uniform prevalence of urinary CMV shedding among 6- to 11-year-olds, the smaller age ranges examined in the present analysis demonstrate that the prevalence of urinary CMV shedding is significantly different between children aged 6--8 and 9--11 years. The results from the previous study indicated that urinary CMV shedding prevalence was associated with sex and household income level among 6- to 49-year-olds \[[@CIT0012]\]; however, these associations were not observed in this analysis restricted to 6- to 19-year-olds. The present study suggests that age is the predominant demographic factor associated with urinary CMV shedding among children and adolescents in the United States.

The strong association between age and CMV shedding seen in this study is consistent with the current literature \[[@CIT0002], [@CIT0003], [@CIT0008], [@CIT0012], [@CIT0020]\]. Because the lower age limit of the study was 6 years, it was not possible to characterize urinary CMV shedding in very young children \[[@CIT0020], [@CIT0021]\]. A previous study showed that 21% of 1- to 5-year-olds in the United States were CMV seropositive \[[@CIT0021]\]. Other studies have shown that the prevalence of urinary CMV shedding in postnatally infected children who are not attending daycare and are less than 6 years of age ranges from 1% \[[@CIT0022]\] to 36% \[[@CIT0023]\]. As expected, we found a higher prevalence of CMV IgG antibody among 6- to 8-year-olds (38%); however, among these individuals, the prevalence of urinary CMV shedding was 34%. Given the similar prevalence of urinary CMV shedding between 1- to 5-year-olds and 6- to 8-year-olds, children over the age of 5 should also be considered an important risk group for CMV transmission. This is particularly important in the context of potential CMV transmission to seronegative pregnant women who have CMV-infected children, which could have implications regarding the incidence of congenital infections \[[@CIT0024], [@CIT0025]\].

It is interesting to note that higher BMI was independently associated with a lower prevalence of urinary CMV shedding among CMV IgG-seropositive individuals. Previous work has shown that obese 4- and 6-year-olds are more likely to be CMV IgG seropositive \[[@CIT0026]\], but, to our knowledge, the association between BMI and CMV shedding has not been studied in pediatric populations. The lower prevalence of urinary CMV shedding observed among obese CMV IgG-seropositive persons in this study may be explained by several factors. The natural history of CMV infections has been shown to be influenced by the gut microbiome \[[@CIT0027], [@CIT0028]\], which differs between obese and nonobese individuals \[[@CIT0029]\]. It is also possible that obese individuals acquire infection earlier than nonobese individuals and therefore had time to control their infection before participating in this study. This hypothesis cannot be tested using cross-sectional data. The potential link between obesity and the natural history of CMV requires further investigation.

Given that these data are cross-sectional, it was unclear whether participants were shedding CMV due to primary infections, reactivation of latent infections, and/or reinfection with a different strain \[[@CIT0001]\]. In addition, because CMV shedding was only examined in urine at a single point in time and CMV shedding can occur dynamically in most bodily fluids \[[@CIT0002], [@CIT0020], [@CIT0030], [@CIT0031]\], this study likely underestimates the true prevalence of CMV shedding. In addition, this study did not measure several factors that have previously been shown to be associated with urinary CMV shedding in pediatric populations, such as current daycare attendance \[[@CIT0002], [@CIT0009], [@CIT0032]\]. This study was also limited due to missing data among examined participants, particularly on CMV outcomes. Previous analyses of CMV data in this database have largely assumed missing data on CMV outcomes were missing at random within age-sex-race strata \[[@CIT0011], [@CIT0012]\]. However, we found that missing data on CMV IgG antibody and urinary CMV shedding status were associated with variables beyond age, sex, and race/ethnicity. Given that these data were not missing by chance alone, we handled missing data by multiple imputation using chained equations \[[@CIT0019]\]. Finally, these data represent non-Hispanic whites, non-Hispanic blacks, and Mexican Americans in 1999--2004 and may not be generalizable to the current US population of children and adolescents.

Data on the genotype distribution of CMV in general populations are limited. This study shows the most prevalent CMV strains observed in 6- to 19-year-old urinary CMV shedders were gB1 and gH2, which is consistent with reported genotype distributions in transplant patients and congenitally infected infants \[[@CIT0007], [@CIT0017], [@CIT0033]\]. Multiple CMV strains, defined by the detection of 1 or more variants of a single glycoprotein, have been documented in both immunocompromised and healthy populations \[[@CIT0007], [@CIT0010], [@CIT0033]\]. Although not all CMV gB variants (eg, gB5, gB6, gB7) were genotyped in this study \[[@CIT0037]\], 14% of the pediatric sample had multiple infections based on the 4 gB genotypes that were examined. These data may have implications for transmission of viral diversity as well as vaccine development. It is important to note that this study provides a national perspective, and the distribution of CMV genotypes may vary based on geographic location, owing to global variation in CMV genotypes and geographic differences in migrant populations in the United States \[[@CIT0007], [@CIT0017], [@CIT0040]\].

CONCLUSIONS {#s11}
===========

In summary, young children above the age of 5 are potentially a high-risk source of CMV transmission given their high prevalence and magnitude of urinary CMV shedding. This study also suggests that obesity may influence the natural history of CMV infection among children and adolescents, but this hypothesis warrants further investigation.
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###### 

Click here for additional data file.
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